P432 The prevalence of co-infection with HIV, Hepatitis C and TB among patients infected by HIV/AIDS in Senegal

<h3></h3> Hepatitis is the predominant risk factor associated with hepatocellular carcinoma. <h3>Objective</h3> The aim of the present research is to carry out epidemiological studies concerning the hospital out-come management of Hepatitis C co – infection with HIV and TB in a well defined hospital based population. Materials and <h3>Methods</h3> Epidemiological studies were carried out among 1320 patients admitted at Kaolack hospital concerning the hospital out-come management of hepatitis C (HCV) and Co – infections with HIV and TB over a period of four years (2006 – 2010). The grand diagnostic kits were used to analyze blood samples for HBV, HCV and HIV while sputum samples were analyzed for TB using the Zel Nielsen (ZN) staining technique. <h3>Results</h3> A CD4 lymphocyte count of 0–200 cells/mml was found in 625 (47.3%) individuals. Out of these, 393 were found to be in WHO stage l clinical status. A further 409 with CD4 count of 201–400 cell/mml were grouped as stage lll (254) and stage IV (155).These together was determined as being eligible for anti-viral therapy. Of background Viral hepatitis constitutes a major public health problem world wide. Viral those eligible for anti-viral 52 and 80 were infected with HCV and HIV respectively. With respect to subjects management outcome in the hepatitis C infected subjects, follow-up was lost in 44(71.0%) while 11(17.7%) subjects survived and 7 (11. 3%) died. Similarly, subjects managements out-come amongst HIV and TB co-infected with HCV infections were fallow-up was lost in 34 (77.3%), 7 (15.9%) survived and 3 (6.8%) died. With respect to TB smear positive co-infected with HCV, fallow-up was lost, 6 (20.6%) survived while 6 (20.6%) died. <h3>Conclusion</h3> In respect to CD4 lymphocyte count and WHO clinical staging subjects were selected for Antiviral therapy management out-come showed that there was loss of fallow-up for majority of the subjects.